229 related articles for article (PubMed ID: 25294104)
1. Effects of varenicline and cognitive bias modification on neural response to smoking-related cues: study protocol for a randomized controlled study.
Attwood AS; Williams T; Adams S; McClernon FJ; Munafò MR
Trials; 2014 Oct; 15():391. PubMed ID: 25294104
[TBL] [Abstract][Full Text] [Related]
2. Retraining automatic action tendencies for smoking using mobile phone-based approach-avoidance bias training: A study protocol for a randomized controlled study.
Machulska A; Kleinke K; Eiler TJ; Grünewald A; Brück R; Jahn K; Niehaves B; Gethmann CF; Klucken T
Trials; 2019 Dec; 20(1):720. PubMed ID: 31831080
[TBL] [Abstract][Full Text] [Related]
3. Effects of varenicline on smoking cue–triggered neural and craving responses.
Franklin T; Wang Z; Suh JJ; Hazan R; Cruz J; Li Y; Goldman M; Detre JA; O'Brien CP; Childress AR
Arch Gen Psychiatry; 2011 May; 68(5):516-26. PubMed ID: 21199958
[TBL] [Abstract][Full Text] [Related]
4. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.
Evins AE; Cather C; Pratt SA; Pachas GN; Hoeppner SS; Goff DC; Achtyes ED; Ayer D; Schoenfeld DA
JAMA; 2014 Jan; 311(2):145-54. PubMed ID: 24399553
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.
Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; Brauer R; Kessler PD; Kalnik MW; Fahim RE; van Schayck OC
BMC Public Health; 2012 Dec; 12():1052. PubMed ID: 23216646
[TBL] [Abstract][Full Text] [Related]
6. Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.
Hartwell KJ; Lematty T; McRae-Clark AL; Gray KM; George MS; Brady KT
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):92-8. PubMed ID: 23421569
[TBL] [Abstract][Full Text] [Related]
7. The effects of varenicline on stress-induced and cue-induced craving for cigarettes.
Ray LA; Lunny K; Bujarski S; Moallem N; Krull JL; Miotto K
Drug Alcohol Depend; 2013 Jul; 131(1-2):136-42. PubMed ID: 23298651
[TBL] [Abstract][Full Text] [Related]
8. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
[TBL] [Abstract][Full Text] [Related]
9. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
10. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
11. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
12. The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure.
Lawson SC; Gass JC; Cooper RK; Tonkin SS; Colder CR; Mahoney MC; Tiffany ST; Hawk LW
Psychopharmacology (Berl); 2021 Feb; 238(2):599-609. PubMed ID: 33219852
[TBL] [Abstract][Full Text] [Related]
13. Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers.
Gass JC; Wray JM; Hawk LW; Mahoney MC; Tiffany ST
Psychopharmacology (Berl); 2012 Sep; 223(1):107-16. PubMed ID: 22476610
[TBL] [Abstract][Full Text] [Related]
14. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
15. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
16. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of varenicline in achieving abstinence among waterpipe tobacco smokers - study protocol for a randomized controlled trial.
Zahid R; Dogar O; Mansoor S; Khan A; Kanaan M; Jawad M; Ahluwalia JS; Siddiqi K
Trials; 2017 Jan; 18(1):14. PubMed ID: 28077163
[TBL] [Abstract][Full Text] [Related]
18. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
19. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
20. Culturally-tailored smoking cessation for American Indians: study protocol for a randomized controlled trial.
Choi WS; Faseru B; Beebe LA; Greiner AK; Yeh HW; Shireman TI; Talawyma M; Cully L; Kaur B; Daley CM
Trials; 2011 May; 12():126. PubMed ID: 21592347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
